Market Overview

Morgan Stanley: Illumina's Q1 Guidance Puts 2019 Targets In Question

Morgan Stanley: Illumina's Q1 Guidance Puts 2019 Targets In Question

Illumina, Inc. (NASDAQ: ILMN) announced 2019 revenue growth guidance of 13-14 percent, and much of this revenue growth is expected to be in the back half of the year.

Yet the company's first-quarter guidance raises concerns around whether Illumina can meet its full-year target, according to Morgan Stanley.

The Analyst

Analyst Steve Beuchaw maintains an Equal-Weight rating on Illumina with a $288 price target. 

The Thesis

Illumina reported a marked deceleration in revenue growth to 11 percent in Q4 versus the 20-percent growth generated in the previous four quarters, Beuchaw said in a Wednesday note.

The Q4 results were pre-announced and the 2019 guidance was as expected, the analyst said. 

Illumina’s Q1 guidance grabbed attention, as it reflects a deceleration in growth to single digits and is 6-percent below consensus expectations, Beuchaw said. Investor feedback “highlights a lack of confidence” in the company being able to achieve its 2019 guidance, he said. 

The 2019 guidance indicates large population sequencing projects that will impact near-term results, the analyst said. 

Morgan Stanley lowered its revenue estimates for 2019 and 2020 by 6.7 percent and 8 percent, respectively. The firm also lowered margin expansion expectations, resulting in a downward revision of EPS estimates for 2019 and 2020 from $6.83 to $6.38 and from $8.28 to $7.69, respectively.

Price Action

Illumina shares were down 4.86 percent at $271.39 at the time of publication Wednesday. 

Related Links:

The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance

Earnings Scheduled For January 29, 2019

Latest Ratings for ILMN

Nov 2019Initiates Coverage OnBuy
Oct 2019MaintainsHold
Oct 2019MaintainsOverweight

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Steve BeuchawAnalyst Color News Guidance Price Target Reiteration Analyst Ratings Best of Benzinga


Related Articles (ILMN)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.

Latest Ratings

MJP MorganMaintains13.0
IPARDA DavidsonMaintains76.0
TGTMorgan StanleyMaintains130.0
VCMorgan StanleyMaintains52.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

TMS' Value As Carrier Procurement Tool "Severely Underutilized," Gartner Analyst Says

The British Gambit: How To Convince Your Opponent You Mean Suicide